• Hilcorp Energy reported steep declines for EBITDA and revenue in 3Q19, causing its bonds to soften even as investors are primarily focused on the upcoming transformative acquisition of BP’s midstream and upstream assets in Alaska, said two sources familiar with the matter. On the earnings call, management gave investors a glimpse of how it plans to finance the USD 5.6bn purchase, which will include around USD 1bn in unsecured notes, they said.

    Management said on the call held 20 November that alongside the new notes, the company will finance the acquisition with a minimum of USD 500m of equity, a revolver draw and cash, two of the sources said. The deal is expected to close by 2Q20.

    The USD 5.6bn purchase includes a base price of USD 4bn payable through 2020 and USD 1.6bn of additional earnout consideration after July 2021.

    Hilcorp expects a USD 600m working capital adjustment to take place in its favor as the acquisition closes next year. The company will pay a deferred payment of USD 1bn to the seller in 4Q20, contingent on the performance of the asset, both sources added.

    Management has a long-term leverage target of below 2.5x and intends to structure the acquisition financing to keep leverage at 3x or under, one of the sources and an additional source said.

    Hilcorp’s USD 500m 5% senior unsecured notes due 2024 traded today at 88.5 to yield 7.825%, up from the 87-87.5 range the day before the earnings call, but down from the 89 area before the results were released. The notes traded at 92.5 yielding 6.7% before the acquisition announcement in August, according to MarketAxess.

    The USD 500m 5.75% senior unsecured notes due 2025 traded yesterday at 87 to yield 8.63%, down from the 88-89 area before the earnings release and 94.5 yielding 6.87% before the acquisition announcement.

    Investors view the BP assets as attractive at 100% oil production with a 3% decline rate, the first two sources said. Pro forma production is expected to increase to 230,000-240,000 barrels per day, compared to 150,000 in 3Q19, they said.

    “This acquisition is essentially supposed to double the size of the company,” one of the sources said.

    However, the existing Hilcorp entity booked negative organic earnings trends during the third quarter, with EBITDA declining 37% to USD 187m and revenue down 24% to USD 468m, two of the sources said.

    For full-year 2019, Hilcorp is guiding USD 2bn-USD 2.2bn of revenue and USD 900m-USD 1bn of EBITDA, both sources added. The company expects to have USD 1.2bn-USD 1.3bn drawn on the revolver at year-end and roughly 2.9x of leverage.

    As of 30 September, liquidity stood at USD 876m given USD 241m of cash and USD 635m of revolver availability, two of the sources said. Pro forma the transaction, the company expects to increase its revolver size to USD 2.5bn-USD 3bn from USD 1.7bn currently.

    Total debt currently stands at USD 2.7bn, they added. With LTM EBITDA of USD 1.043bn, the company is 2.6x levered, one of the sources added.

    Hilcorp did not respond to a request for comment.

  • Helix Generation reported year-over-year improvement in EBITDA and gross margin in 3Q19, according to two sources familiar with the matter.

    The LS Power-owned borrower booked USD 49m of EBITDA for the quarter, compared to USD 42m in 3Q18. Gross margin for the quarter totaled USD 76m, up from USD 69m last year, the sources said.

    The company’s USD 857m Libor+ 375bps TL due 2024 is quoted today in the 95.687/96.542 context, compared to 94.896/95.938 before the earnings, according to Markit.

    The company is levered 12.8x, based on LTM EBITDA to USD 70m and USD 894m of total debt, one of the sources said.

    Power pricing is expected to improve over the next two years in the New York City Zone J region in which Helix’s Ravenswood Generating Station operates, the sources said. That should lead to further earnings improvement in 2020, they added.

    Helix’s Ravenswood power plant, a 2,480 megawatts, multiple-unit natural gas generating facility located in Queens, provides 5% of New York City’s power demand (estimated 20% of peak load), according to a Moody’s report from December.

    “People are less concerned about the quarter per se though and are paying more attention to year-end for 2020 guidance. We want to see the impact of the tightening supply and higher capacity prices in Zone J,” one of the sources said.

    As of 30 September, liquidity consisted USD 15m of cash in addition to availability under its revolver, the sources said.

    LS Power did not respond to a request for comment.

  • Talen Energy Supply narrowed its EBITDA and free cash flow guidance for fiscal year 2019 as it unveiled softer 3Q19 earnings earlier this month, according to two sources familiar with the matter. The move marks the second time Talen has tightened its guidance this year.

    The Riverstone-backed power company expects EBITDA in the range of USD 600m-USD 650m for FY19, compared to previous guidance of USD 600m-USD 700m. Free cash flow guidance was revised to USD 20m-USD 80m from previous guidance of USD 10m-USD 110m, the sources said.

    The company already tightened EBITDA and free cash flow guidance in August with its 2Q19 earnings report. Initial 2019 EBITDA guidance stood at USD 575m-USD 725m and was tightened to USD 600m-USD 700m. Free cash flow guidance for the year was also changed at that time to USD 10m to USD 110m from USD 0m to 120m, as reported.

    Talen’s USD 625m 10.5% senior guaranteed notes due 2026 dipped nearly two points after the 3Q19 earnings were released, trading on 21 November at 84.75 to yield 14.306%, according to MarketAxess. They have retraced slightly since then, trading today (25 November) at 85.12 to yield 14.206%.

    On the earnings front, the company booked USD 213m in adjusted EBITDA, down 17% from USD 257m in 3Q18, attributed to an expected weakness in PJM capacity, the sources said.

    Sources expect the weakness on the capacity side to persist until the results from the 2020/2021 capacity auction are actualized. In that auction, Talen offloaded 94% of its capacity.

    “This quarter was weak, but in line with expectations. We’re really just waiting for management to provide more insight on just how much of a boost the company will get in 2021 from the auction,” one of the sources said.

    As of 30 September, the company’s liquidity totaled USD 844m through USD 33m of cash and USD 811m of revolver availability. The company is now levered 6.4x, based on USD 718m of LTM consolidated adjusted EBITDA and USD 4.6bn of total debt.

    Talen’s nearest maturity trading in size, its USD 550m 6.5% senior unsecured notes due 2025, softened slightly to 76 to yield 12.662% post earnings, from trades at 76.25 in early November. The notes leaked further today (25 November) to 75.75 to yield 12.76%, according to MarketAxess.

    Meanwhile, the issuer’s USD 750m 7.25% senior secured notes due 2027 ticked up slightly to trade at 102 on 15 November for a 6.726% yield, from 101.593 before the earnings report. They traded today at 102 for a 6.723% yield.

    Talen did not respond to a request for comment.

  • Vertiv reported a 6.7% year-over-year gain in EBITDA in 3Q19, while revenue remained roughly flat, according to two sources familiar with the situation. Management commented on the call that the business could face a few choppy quarters ahead due to a cyclical trough, but that they expect a rebound after that.

    The Platinum-owned company also said that it still plans to go public, and is examining options between a direct listing, IPO and sale to a public company, the sources said. In June, Vertiv said it would file an S-1 with the Securities and Exchange Commission before the end of the year, as reported.

    EBITDA for the quarter grew to USD 136.1m, from USD 127.6m in 3Q18. Revenue eased slightly to USD 1.070bn, compared to USD 1.077bn in 3Q18, the sources said.

    As of 30 September, liquidity totaled USD 400m through USD 149m of cash and USD 251m of revolver availability. Factoring in USD 93m of cash collateral supporting the borrowing base, liquidity totals USD 307m. The company generated adjusted free cash flow of USD 43.6m in the quarter, compared to a cash burn of USD 35m last year, sources added.

    Vertiv is 6.6x levered through USD 3.63bn of total debt and USD 550m of LTM EBITDA, or 6.3x net of USD 149m in cash. Factoring in only opco debt, the company has 5.6x gross leverage.

    The USD 500m 12% senior unsecured holdco PIK toggle notes due 2022 traded up to 94.25 to yield 15.102% yesterday (20 November) from trades at 85.25 earlier this month before the earnings report, according to MarketAxess.

    Vertiv’s USD 750m 9.25% senior unsecured notes due 2024 have been trending higher for the last month on the expectation of favorable earnings. The notes traded as high as 99.5 to yield 9.375% on 18 November from trades at 95.25 to yield 10.503% at the beginning of the month. The notes have settled today at 98 to yield 9.769%.

    The USD 2.07bn Libor+ 400bps TL due 2023 was quoted today at 96.33/97.08, up from trades at 94.25/95.25 before the earnings report and from 93.8/94.85 earlier this month, according to Markit.

    Vertiv did not respond to an inquiry seeking comment.

  • Exide Technologies lowered its EBITDA and revenue guidance for its 2020 fiscal year last week as it reported mixed earnings for 2Q20, according to two sources familiar with the situation. The company cited higher input costs as a drag on earnings, the sources said.

    The company, which makes and recycles lead acid batteries, gave midpoint guidance of USD 2.625bn for revenue, USD 127.5m for EBITDA and a cash burn of USD 52.5m. The midpoint of previous guidance was USD 2.725bn for revenue, USD 134m for EBITDA and a cash burn of USD 47.5m, said the sources.

    For the quarter ended 30 September—Exide’s fiscal 2Q20—the company reported revenue of USD 572m, an 18% drop from the prior year period. Exide booked around USD 28m of EBITDA, compared to USD 22m year-over-year and USD 17.4m sequentially. The company said higher input costs, in particular lead prices, were the main driver of the mixed results, sources said.

    Lead prices hit a recent peak at the end of October at USD 1.02 per pound before falling as low as USD 0.89 per pound earlier this week. As of today, prices have risen slightly to USD 0.91 per pound—in line with prices from this time last year.

    The company expects lead prices to rise again, translating to lower revenue and EBITDA generation for the year. Management said that dynamic contributed roughly a third of the reduction in the company’s guidance, according to one of the sources.

    As of 30 September, Exide’s liquidity totaled USD 85m through USD 32m of cash and USD 53m of revolver availability. The company is 9.7x levered, based on USD 123.3m of LTM EBITDA and USD 1.2bn of total debt.

    Management did not give a material update on its previously announced plans to sell the company’s European segment, which makes up more than 60% of Exide’s EBITDA, the sources said.

    The company’s capital structure contains a USD 150m 4.5% PIK/10.75% cash super-priority note due 2021, a USD 375m 11% PIK/3% cash exchange priority note due 2024, a USD 159m 11% PIK/3% cash first lien note due 2024, and a USD 290m 7.25% PIK 1.5 lien note due 2027.

    Exide did not respond to a request for comment.

  • Centene’s pending acquisition of WellCare puts the health insurance provider on the path to investment grade status across all agencies if the targeted USD 700m of synergies are realized. But the merger is still contending with regulatory hurdles, and several macro policy and litigation risks could jeopardize the borrower’s deleveraging timeline, according to five sources following the deal.

    Led by Barclays, the company is marketing a still-fluid structure consisting of USD 7bn of senior unsecured notes, split between USD 2.5bn – USD 3bn senior unsecured notes due 2027, USD 3bn – USD 3.5bn senior unsecured notes due 2029 and a USD 750m add-on to its existing 4.75% notes due 2025.

    The company circulated talk for the 2027 notes earlier today at 4.5%-4.625%, with the 2029 notes talked at 4.75%-4.875%. The add-on is talked at 102.25-102.75.

    The roadshow began last Friday (15 November). Books closed at 4:30pm ET for the East Coast and will close at 9am ET tomorrow for the West Coast.

    In March 2019, Centene announced its intentions to acquire WellCare for USD 17.3bn. In June, the transaction was approved by stockholders at both companies. As of today, the merger has received approval from 25 states and still requires approval from New Jersey and Illinois.

    “They still need approval from two states, so it’s not a done deal yet. The sooner they get the deal done, the sooner they can start integrating the two companies,” one of the sources said.

    Pro forma the deal, Centene’s debt load more than doubles to USD 15.664bn from USD 7.041bn. Along with the proposed notes, the capital structure contains: a USD 1.45bn term loan due 2024, several tranches of existing notes at Centene coming due between 2022-2026 and new exchange notes.

    At the beginning of November, Centene announced exchange offers at par for all outstanding WellCare notes: the USD 750m 5.375% notes due 2026 and USD 1.2bn 5.25% notes due 2025.

    Pro forma consolidated leverage comes in at 3.4x, based on USD 15.664bn of pro forma total debt and USD 4.661bn of combined adjusted EBITDA. That’s higher than Centene’s standalone leverage prior to the deal of 2.1x.

    Meanwhile, the deal brings liquidity to roughly USD 11.07bn through USD 9.17bn of cash and USD 1.9bn of availability on a USD 2bn revolver due 2024.

    Excluding synergies, sources expect Centene to generate roughly USD 3bn of free cash flow – or 19% of total debt — in the first year of the acquisition through USD 4.661bn of adjusted EBITDA, USD 1bn of capital expenditures and USD 700m of pro forma interest expense.

    IG Synergies

    Centene is projecting USD 700m of total run-rate synergies, with roughly USD 500m by year two of the acquisition.

    If the company follows through on the expected synergies, sources expect the company to be upgraded to investment grade across the board. So far, the company has two investment grade ratings, BBB- from S&P and BBB- from Fitch. Moody’s still rates it at Ba1, with a stable outlook.

    Moody’s places the company’s debt to capital financial leverage ratio in the 54% range and expects it to decline to 41% by year-end 2020. Among other factors, the ratings agency would consider an upgrade if the company maintained a Moody’s adjusted financial leverage of 40% or below, debt-to-EBITDA below 2.2x and a further reduction in Medicaid concentration, according to a release.

    Still, given an uncertain future for healthcare in the US, some sources were skeptical that Centene would be able to achieve the targeted synergies.

    “The thesis of this deal is that they will achieve these synergies and until then, you have to deal with the elevated leverage,” one of the sources said. “It’s a little bit like picking up nickels in front of a steamroller – you’re not getting enough yield for the elevated leverage and the potential that these synergies never come through.”

    2020 and Beyond

    In particular, Centene’s and the healthcare space’s future remain uncertain leading up to, and beyond, the 2020 election, three of the sources said.

    The acquisition is expected to not only solidify Centene’s position at the top in the Medicaid provider space, but also expand its coverage in the private Medicare space.

    And depending on which Democratic contender is chosen as the party’s candidate, Centene’s outlook past 2020 could be drastically different, the sources said. For example, Elizabeth Warren and Bernie Sanders are strong proponents of “Medicare for All,” which would ultimately do away with private insurance.

    “If either Warren or Sanders win the [presidency] and push forward this plan, Centene, like many other insurers, will be left overexposed on the private insurance front,” one of the sources said.

    To Centene’s advantage, there are several candidates with proposals that leave room for private insurance rather than doing away with it altogether. But even those proposals could shrink Centene’s coverage space, impacting growth and market share opportunities going forward, the sources said.

    Another major risk facing Centene is the possible repeal of the Affordable Care Act.

    Centene’s individual Obamacare coverage contributes roughly one-third to its standalone EBITDA and extends to nearly 1.9m members across 20 states through government exchanges, making it the largest provider, according to company documents.

    A decision in Texas v. Azar, the most recent case to challenge the Affordable Care Act, is expected any day now, according to media reports. The case is in the 5th Circuit Court of Appeals and could go to the Supreme Court. The Supreme Court’s decision would impact Centene and other insurers on top of any people that receive their health coverage from programs created under the law.

    Sources expect Centene’s proposed notes to come wide to those of Baa3/BBB+ rated Humana, an IG-rated peer in the insurance space, noting that Humana is more diversified, especially in its group insurance offerings.

    Humana’s Baa3/BBB+ USD 500m 3.125% senior unsecured notes due 2029 traded today at 101.493 to yield 2.943%, up from trades at par in October, according to MarketAxess.

    Centene did not respond to a request for comment. Barclays declined to comment.

  • Cooke Omega bonds traded up after the fish products and aquaculture company reported year-over-year EBITDA and revenue spikes for 3Q19, according to two sources familiar with the matter.

    The USD 330m 8.5% senior unsecured notes due 2022 last traded yesterday at 98.75 to yield 8.971%, up from pre-earnings levels of 97 to yield 9.632% on 1 November, according to MarketAxess.

    Cooke booked USD 99.2m of revenue for 3Q19, up roughly 7% from USD 92.9m in 3Q18, driven by an increase in production volumes, the sources continued. EBITDA jumped 35% year-over-year to USD 24m, compared to USD 17.9m in 3Q18. The company’s production totaled 86.783 tons in 3Q19, up 6% year-over-year. Cooke also credited the uptick to a larger fish catch, which totaled 738,623 for the quarter, up 7.5% year on year.

    Revenues for the animal nutrition segment increased 10% on the year, offset by a slight decrease in the human nutrition segment, according to the sources.

    The positive earnings report combined with trading momentum could incentivize management to explore refinancing options, noted one of the sources. In addition to the 2022 notes, the balance sheet carries an ABL revolver due 2023 with USD 24m drawn. As of 30 September, the company’s liquidity consisted of USD 42.7m of availability on the revolver and USD 12m of cash, both sources said.

    Cooke as of 3Q19 was levered around 4.8x based on USD 349.4m of total debt and USD 73m of LTM EBITDA, the sources continued. On an LTM basis, the company generated roughly USD 15m (4.3% of total debt) of free cash flow, based on USD 73m of EBITDA, USD 29m of capex and USD 29m of interest expense.

    Cooke announced earlier this year that it is considering the strategic sale of its human nutrition segment, as reported, but management in the recent earnings report didn’t provide an update on the sale process, the sources said.

    Cooke did not respond to a request for comment.

  • NOVA Chemicals has tapped its liquidity to fund a USD 1.08bn damages payment while it awaits the results of its appeal against the litigation, according to three sources following the situation. The payment, to Dow Chemicals, came after NOVA reported disappointing 3Q19 earnings, the sources said.

    In September, the Court of the Queen’s Bench in Alberta, Canada signed an order for NOVA to pay Dow USD 1.08bn on 10 October for damages incurred by Dow from 2001-2012 at the companies’ jointly-owned ethylene plant in Joffre.

    Last year, the court ruled that Mubadala-owned NOVA failed to operate the ethylene asset at full capacity. NOVA appealed the decision in April 2019, but oral arguments are not scheduled to begin until June 2020, as reported in NOVA’s 3Q19 earnings last week.

    NOVA used its USD 500m delayed draw term loan, USD 100m of its US securitized accounts receivable facility and USD 480m of cash on hand to fund the payment. Pending the results of the litigation, sources expect the company to pay roughly USD 250m-350m for additional damages potentially incurred in the period after 2012, the sources said.

    The payment leaves NOVA with USD 1.734bn of liquidity, through USD 279m of cash and USD 1.455bn of revolver availability, two of the sources said.

    NOVA reported adjusted EBITDA of USD 199m for the quarter, down 41% from last year and below investor expectations of USD 230m-240m, the sources said. That puts leverage at 4.2x based on USD 3.953bn of total debt and USD 940m of LTM EBITDA, they added.

    Revenue for the quarter totaled USD 846m, down 26% from USD 1.14bn in 3Q18. The drop was attributed to lower ethylene and polyethylene prices as well as weaker ethylene sales volumes, the sources said.

    Sources said they expect the company to burn roughly USD 720m-USD 820m in 2020. That’s based on USD 900m-1.1bn of EBITDA, USD 220m of interest expense, USD 1bn of capex, USD 250m-USD 350m for the potential DOW litigation payment and USD 250m for a dividend payment.

    NOVA’s bonds have leaked slightly since the report, according to MarketAxess. The USD 1.05bn 5.25% senior unsecured notes due 2027 traded today at 101 to yield 5.085%%, down from trades at 103-104 early last week. The USD 1.05bn 4.875% senior unsecured notes due 2024 to trade at 101 to yield 4.617% today, from trades at 101-102 early last week.

    Trading levels have been bolstered by a potential sale of NOVA, the sources said. Earlier this year, Reuters reported that the company had received a bid from CP Chemical valuing it at USD 15bn.

  • Maxar Technologies is focusing its near-term refinancing pitch on a new fleet of satellites that it says should catapult the cash-burning company to positive free cash flow within the next two years, according to five sources following the deal.

    The new capacity should lead to a more sustainable credit profile in time. But Maxar’s capex spend will remain elevated for the next two years, so lenders must have a high degree of conviction in a successful launch, sources said.

    “These satellites go live two years before the bond matures, so you have to believe that the company is going to turn things around and these satellites will be worth it,” one of the sources said.

    Maxar’s aspirational refi pitch follows the failure of its large WorldView-4 satellite earlier this year. Since that event, the company has been focused on reducing its leverage through asset sales and EBITDA growth, as previously reported by Debtwire.

    Led by BofA, the company is marketing USD 1.25bn of B2/B senior secured notes due 2023. A deal roadshow began early last week and continues through tomorrow (14 November), with pricing expected Friday. Price whispers are currently 9%, three of the sources said.

    Proceeds from the deal would repay borrowings under the company’s USD 1.15bn revolver due 2021, as well as its USD 250m TLA-1 due 2020 and USD 250m TLA-2 due 2021. Pro forma leverage is 7x, based on USD 457m of LTM adjusted EBITDA and USD 3.22bn of total debt, according to deal documents.

    If the refinancing is successful, Maxar’s capital structure will comprise of a USD 1.96bn L+ 275bps TLB due 2024, ranking pari passu with the new secured notes. The B2/B TLB is somewhat stressed, at quotes of 88.667/89.667, according to Markit. That equates to a yield to three-year call of 8.86%.

    Maxar is also seeking an amendment to its credit agreement, which is contingent on successful completion of the bond offering. Through that amendment, the company will reduce committed borrowing capacity on the revolver to USD 500m and extend the facility’s maturity to 2023.

    The amendment would also limit Maxar’s leverage, with a maintenance covenant set at 7.25x total leverage as of December 2019, 7.5x as of March 2020 and 7.75x as of September 2021. The covenant steps down to 7.5x in September 2022, 6.5x in March 2023 and 5.75x for each fiscal quarter thereafter.

    Pro forma liquidity comprises USD 500m of borrowing capacity under the amended revolver, and USD 81m of cash.

    Promising the world 

    Maxar provides satellite technology, imagery and services to government and commercial customers. As of 2018, it derived just over half its revenue from space systems, with imagery the second biggest driver of sales and services coming in last.

    The company is aiming to launch six WorldView Legion satellites in 2021 to grow its imagery and space systems segments. Each satellite costs roughly USD 100m, and has half the capacity of the single WorldView-4 satellite—meaning together, the six new satellites should triple the company’s imaging capacity.

    As such, a successful launch would be a big step forward for Maxar, said buysiders looking at the deal. “It’s better for the company to spread its risk across several satellites rather than one satellite and these are cheaper in cost and lighter in weight,” one of the sources said.

    After the satellites come online in 2021, the company expects to generate USD 300m-USD 350m in free cash flow, executives said during the company’s 3Q19 earnings call. That’s based on USD 665m in adjusted EBITDA, USD 100m-USD 150m of capex and USD 215m of interest costs.

    However, elevated capex spending in the run-up to the launch will weigh on cash flow, three of the sources said. They forecasted a cash burn roughly USD 150m of cash in 2020, modeling for roughly USD 440m in adjusted EBITDA, USD 375m of capex and USD 215m of pro forma interest expense.

    To boost liquidity and help offset its constrained cash flow profile over the next two years, Maxar recently entered into a sale-leaseback agreement for its Palo Alto manufacturing facility for roughly USD 291m in gross proceeds. The sale-leaseback is expected to close by the end of the year.

    The company has included a special call feature in the proposed secured bonds that would allow the company to use the proceeds from the Palo Alto sale to call up to USD 300m of the proposed bonds at par. Even if it doesn’t complete the bond deal, the company still expects to use the proceeds from the Palo Alto sale to pay down its TLA-1.

    But while these measures—and the maintenance covenant in the revolver—go some way to mitigating Maxar’s high leverage as it moves towards launch date, lenders are still being asked to take something of a leap of faith, sources said.

    “Having the maintenance test in your back pocket is certainly reassuring to a degree, but still EBITDA growth is not a given,” one of the sources said. “I’m viewing it more on whether the satellites will be able to launch successfully.”

    Buysiders agreed that the company is posed for a successful launch, according to two of the sources. “The first satellite failure was more specific to that satellite. The chances of them launching successfully are much higher this time around. They’re also not relying on just one satellite for the revenue growth, so the chances are higher,” one of the sources said.

    While Maxar does not have a perfect comp, some sources evaluated the deal against fixed satellite operator Intelsat. Moody’s referred to peers such as Triumph Group, an aerospace services and part supplier, and Moog Inc, a motion and fluid control manufacturer for the aerospace and defense sectors—as comparison points.

    Sources said Maxar’s bond should price between current yields on the Intelsat Jackson 8% secured notes and 8.5% unsecured notes. The B1/B USD 1.35bn 8% senior secured notes due 2024—issued through the Intelsat Jackson entity—traded today at 102.875 to yield 4.291%, in line with recent levels, far tighter than whispers on the Maxar secureds.

    Pricing should come closer to the USD 2.95bn 8.5% Intelsat Jackson senior unsecured notes due 2024, they said. Those bonds traded today at 97 to yield 9.27%, down from trades yesterday at par and earlier this week at 101, according to MarketAxess.

    Triumph’s Caa2/CCC USD 500m 7.75% senior unsecured notes due 2025 traded on 8 November at 102.875 to yield 6.864%, in line with recent levels. Moog’s Ba3/BB USD 300m 5.25% senior unsecured notes due 2022 last traded today at 101.75 to yield 3.527%, in line with recent levels, according to MarketAxess.

    Maxar did not respond to a request for comment. BofA declined to comment.

  • Party City’s capital structure and equity plummeted today as the company reported a steep decline in earnings for 3Q19 ended 30 September and a weak outlook for the fourth quarter, according to four sources following the company. The company attributed its 71% year-over-year quarterly EBITDA dive to macro dynamics like a global helium shortage and Chinese tariffs – but investors were most spooked by the company’s poor sales during its critical Halloween selling season, the sources said.

    “I would’ve thought [Halloween sales were] a bread-and-butter part of their business, but I guess not. Now, they’ll have to wait until next year to fix it,” one of the sources said.

    The issuer’s USD 500m 6.625% senior unsecured notes due 2026 fell more than 15 points today to 80.5 yielding 10.773% from trades in 96-97 yesterday (6 November), according to MarketAxess. The USD 350m 6.125% senior unsecured notes due 2023 dropped to 91.375 to yield 8.868% from trades at 100.75 yesterday.

    The company’s USD 1.2bn Libor+ 250bps TLB due 2022 (repriced in February 2018) dropped seven points to 91.083/92.458 today from the 98.875/99.444 context yesterday, according to Markit.

    In the equity market, Party City’s stock dove 67% today to USD 2.00 per share and a market cap of USD 188.87m.

    The company provided a glimpse of its post-3Q October sales, since Halloween typically comprises a significant chunk of the issuer’s annual revenue (Debtwire credit analysts estimate that in 4Q18, October contributed roughly 55% of 4Q sales, and that 4Q sales made up more than one-third of annual sales).

    During October of this year, sales per store at its Halloween City pop-ups decreased 20.8% from the prior year. Total monthly revenue was down 7% year-over-year to USD 432.6m for its retail segment, excluding Canadian retail revenue.

    The lower sales per store for Halloween imply that the company is losing market share to other retailers such as dollar stores, two of the sources said.

    Party City lowered its 2019 adjusted EBITDA guidance for the second time this year. In 2Q19, it reduced guidance to USD 355m-USD 370m from USD 405-USD 418m. Now, the company is expecting USD 300m-USD 310m.

    Investors are unsure what to make of the about-face. “It’s hard to predict, because this was such a bad miss,” one of the sources said.

    The 3Q19 quarterly results showed adjusted EBITDA fell 71% year-over-year to USD 17.1m, while revenue for the quarter fell 2.3% to USD 540.2m. Total gross profit margin decreased 590bps to 30.6% of net sales, which the company credited to the helium shortage, cost inventory markdowns, higher freight costs linked to Chinese tariffs, increased promotional activity and sales mix shifts.

    At FY19 adjusted EBITDA guidance, leverage would come in at 6.7x at year end – compared to 5.1x at the end of 2Q19. On an LTM basis, the company generated USD 155m of free cash flow (7.6% of total debt), based on USD 339m of adjusted EBITDA, 66m of capex and USD 118m of interest expense.

    As of 30 September, liquidity stands at USD 186.5m through USD 152m of revolver availability and USD 34.5m of cash. Proceeds from the of USD 132m sale of its Canadian business, which closed 1 October, boost liquidity to 318.5m.

    The company plans to close at least 21 more locations in the fourth quarter.

    Party City did not respond to a request for comment.